Toolkit

Email Alert

Sign up to join Advicenne’s Press Releases diffusion list

Contacts

Advicenne
262, rue du Faubourg
Saint-Honoré
 – 3ème étage
F-75008 Paris, France
+33 4 66 05 54 20
investors@advicenne.com

Financial Communications
Ulysse Communication
advicenne@ulysse-communication.com

Consilium
Advicenne@consilium-comms.com

Generic selectors
Exact matches only
Search in title
Search in content

29 April, 2022 - Advicenne 2021 Universal Registration Document made available

21 April, 2022 - Advicenne appoints Philippe Boucheron as Chairman of its Board of Directors

5 April, 2022 - A case report highlights the interest of a long-term treatment with ADV-7103 in dRTA

31 March, 2022 - Advicenne Reports its Financial Results for the Year ended 31 December 2021

30 March, 2022 - Advicenne announces the release of results of a study showing improved quality of life in patients living with DRTa and treated by ADV7103

28 March, 2022 - Advicenne announces the transfer of its shares from Euronext Paris and Euronext Brussels to Euronext Growth Paris on March 30, 2022

21 January, 2022 - Advicenne ordinary shareholders’ meeting approved the project to transfer Advicenne’s shares listing to the Euronext Growth Paris market and delisting from the regulated market of Euronext Brussels

18 January, 2022 - Advicenne reports 2021 sales up 20% to €3.3 million

4 January, 2022 - Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region

27 December, 2021 - Advicenne announces its financial calendar for 2022

20 December, 2021 - Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug Sibnayal™ in dRTA

7 December, 2021 - Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe

3 December, 2021 - Proposed transfer of the listing of Advicenne’s shares to the Euronext Growth Paris market and delisting from the regulated market of Euronext Brussels

29 September, 2021 - Advicenne Reports 2021 Half Year Financial Results

2 July, 2021 - Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA

23 June, 2021 - Advicenne successfully raises circa €9.4m in a placement reserved to a category of persons

22 June, 2021 - Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10m

15 June, 2021 - Advicenne provides an update on its activities following its Annual General Meeting

10 June, 2021 - Live Broadcast of the Annual General Meeting on June 14th, at 11:00 a.m

17 May, 2021 - Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA)

3 May, 2021 - Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal™) and announces Leadership Changes to support Commercialisation

28 April, 2021 - Advicenne Reports its Full-Year Financial Results to December 31, 2020 and Confirms its 2021 Outlook

23 April, 2021 - 2021 Financial Calendar

25 March, 2021 - Precision on the press release dated March 19, 2021

19 March, 2021 - Advicenne expects imminent marketing authorization for ADV7103 (Sibnayal™) for dRTA in Europe

18 February, 2021 - Advicenne Provides an Update as its Operations Evolve

7 January, 2021 - Advicenne Announces the Appointment of Peter Meeus as Chief Executive Officer

10 December, 2020 - Advicenne receives positive CHMP opinion recommending approval of ADV7103 (Sibnayal®) for the treatment of distal renal tubular acidosis (dRTA)

27 October, 2020 - Advicenne obtains non-dilutive loan facility of €4.3 million guaranteed by the French State

25 September, 2020 - Advicenne Presents 2020 Half-Year Financial Report and Provides Update on Outlook and Recent Developments

11 August, 2020 - Advicenne Strengthens Its Financial Structure Through the Implementation of its €20 Million Financing Agreement with the European Investment Bank, with the Drawdown of a First Tranche of €7.5 Million

26 May, 2020 - Advicenne Shareholders Adopt All Resolutions Recommended by the Board of Directors at Its Combined Shareholders Meeting

25 May, 2020 - Advicenne Gears Up for Accelerated Growth

5 May, 2020 - Advicenne Combined Shareholders Meeting to Be Held on May 26 Behind Closed Doors

13 March, 2020 - Advicenne Reports Full-Year 2019 Financial Results and Confirms Operational Outlook for 2020

13 March, 2020 - Advicenne Announces the Appointment of André Ulmann as Interim Chief Executive Officer

10 March, 2020 - Advicenne Makes ADV7103 8 mEq and 24 mEq Prolonged-Release Granules Available Within Framework of French Temporary Authorization for Use (TAU) Scheme

28 January, 2020 - Advicenne Publishes its Financial Calendar for 2020

18 December, 2019 - Advicenne’s Lead Candidate Approved for Orphan Drug Designation in the Treatment of Cystinuria in Europe

15 November, 2019 - Advicenne intends to appoint David Horn Solomon as Chairman of the Board of Directors in line with its International Strategy

28 October, 2019 - Advicenne Presented Additional Efficacy Data on ADV7103 in the Treatment of dRTA at International Pediatric Nephrology Association Congress

27 September, 2019 - Advicenne Publishes its 2019 Half-Year Financial Report

24 September, 2019 - Advicenne Presents 2019 Half-Year Financial Report and Confirms Financial Outlook

20 September, 2019 - Advicenne to present eight posters on the positive results of ADV7103 in the treatment of rare nephrological diseases at major international conferences

4 September, 2019 - Advicenne secures production of ADV7103 through long-term manufacturing supply agreement with Elaiapharm Lundbeck

3 September, 2019 - Advicenne to attend the J.P. Morgan Pan European Small / Mid Cap Conference in London

29 August, 2019 - Advicenne Announces First Patient Enrolled in US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 in distal Renal Tubular Acidosis (dRTA)

26 July, 2019 - Advicenne to Present at the Solebury Trout European Biotech Investor Day in NYC

18 July, 2019 - Financial Visibility and Accelerated Development

13 June, 2019 - Advicenne confirms prevalence of distal renal tubular acidosis (dRTA) and cystinuria at ISPOR conference

12 June, 2019 - Advicenne announces the successful listing of its shares on the regulated market of Euronext Brussels

23 May, 2019 - Advicenne announces its intention to list on the regulated market of Euronext Brussels

30 April, 2019 - Advicenne Publishes its 2018 Annual Financial Report

9 April, 2019 - Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris

21 March, 2019 - Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019

12 March, 2019 - Advicenne Announces Submission of European Marketing Authorization Application (MAA) for ADV7103 as Treatment for Distal Renal Tubular Acidosis (dRTA)

7 January, 2019 - Advicenne’s Flagship ADV7103 Receives Authorization for Pivotal Phase II/III Cystinuria Study in Belgium

21 December, 2018 - Advicenne Publishes its Financial Calendar for 2019

26 October, 2018 - Advicenne Wins Prestigious Prix Galien – Medstartup Award for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcomes

15 October, 2018 - Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada

4 October, 2018 - Advicenne to present additional data on ADV7103 at the European Society for Paediatric Nephrology during its 51st Annual Meeting

25 September, 2018 - Advicenne Prepares its Expansion with Highly Experienced Industry Professionals

20 September, 2018 - Advicenne Reports First-Half 2018 Results and Confirms Outlook for 2018

12 September, 2018 - Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation

5 September, 2018 - Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

2 July, 2018 - Advicenne confirms ADV7103’ safety and efficacy after 24 months in the Phase III Extension Study

31 May, 2018 - Advicenne Announces ADV7103 Poster Presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress

15 May, 2018 - Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe

4 May, 2018 - Advicenne receives authorisation from French regulation authorities to initiate pivotal phase II/III trial of ADV7103 in Cystinuria

30 April, 2018 - Advicenne publishes its annual financial report

18 April, 2018 - Advicenne 2017 Financial Results and Operational Perspectives for 2018

12 February, 2018 - Advicenne announces its financial calendar for 2018 and cash position as of December 31st, 2017

24 January, 2018 - Advicenne appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs

5 January, 2018 - Partial exercise of over – allotment option

5 December, 2017 - Success of the IPO

21 November, 2017 - Advicenne launches IPO on Euronext’s regulated market in Paris

6 November, 2017 - ADV7103: 6-month data presented at ASN

2 November, 2017 - Advicenne announces the registration of its Document De Base in relation to its planned IPO on Euronext’s regulated market in Paris

11 September, 2017 - Advicenne Announces Positive Pivotal Phase III Clinical Data for ADV7103 in Adults and Children Suffering from distal Renal Tubular Acidosis

20 March, 2017 - Advicenne Announces the Closing of a €16 Million Financing Round

Advicenne's, company dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology.

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

© 2019 Advicenne